首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Isolation of Stem-Like Cancer Cells in Primary Endometrial Cancer Using Cell Surface Markers CD133 and CXCR4
Authors:Yi Sun  Toshiko Yoshida  Motonori Okabe  Kaixuan Zhou  Fang Wang  Chika Soko  Sigeru Saito  Toshio Nikaido
Institution:2. Department of Obstetrics and Gynecology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Japan;3. Intensive Care Unit, The Affiliated Hospital of Inner Mongolia medical university, China;4. Department of Anesthesiology, Huashan Hospital of Fundan University, China
Abstract:Endometrial cancer (EC) is the most common familiar gynecologic malignant tumor identified in the female reproductive system and has been increasing yearly. In this study, we will identify the surface markers and stem cell markers related with cancer stem cells (CSCs) of EC. Tissue samples were obtained from endometrial cancer patients during surgical procedures. Single cells were isolated from the tissues for culturing, transfection into nude mice, and histopathology analysis. RT-PCR demonstrated that the cultured cells strongly expressed stemness-related genes, such as c-Myc, Sox-2, Nanog, Oct 4A, ABCG2, BMI-1, CK-18, Nestin and β-actin. The expression of surface markers CD24, CD133, CD47, CD29, CD44, CXCR4, SSEA3 and SSEA4, CD24, and CD133 and chemokine markers such as CXCR4 were measured by flow cytometry. Then the double percentage of CD133+CXCR4+ cells constituted 7.2% and 9.3% in EC cells originated from two different patients, respectively. The CD133+CXCR4+ primary endometrial cancer cells grew faster, exhibited high expression of mRNA of stemness-related genes, produced more spheres, and had higher clonogenic ability than other subpopulations. They are also more resistant to anti-cancer drugs than other subpopulations. These findings indicate that CD133+CXCR4+ cells may possess some characteristics of CSCs in primary endometrial cancer. These cell surface markers may be useful for the development of drugs against CSC molecular targets or as a predictive marker for poor prognosis in primary endometrial cancer.
Keywords:Address all correspondence to: Toshiko Yoshida  MD  PhD  Department of Regenerative Medicine  Graduate School of Medicine and Pharmaceutical Sciences  University of Toyama  2630 Sugitani  930-0152  Toyama  Japan  
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号